-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1921 Preclinical Development of CTX120, an Allogeneic CAR-T Cell Targeting Bcma

Program: Oral and Poster Abstracts
Session: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster I
Hematology Disease Topics & Pathways:
Biological, Therapies, CAR-Ts
Saturday, December 1, 2018, 6:15 PM-8:15 PM
Hall GH (San Diego Convention Center)

Henia Dar1*, Daniel Henderson1*, Zinkal Padalia, MS1*, Ashley Porras1*, Dakai Mu, MS2*, Maeng Kyungah, PhD2*, Seshidhar Police, PhD2*, Demetrios Kalaitzidis, PhD3*, Jonathan Terrett, PhD1* and Jason Sagert, PhD1*

1Immuno-Oncology, CRISPR Therapeutics, Cambridge, MA
2Viral Delivery, CRISPR Therapeutics, Cambridge, MA
3Immuno-Oncology, CRISPR Thereaputics, Cambridge, MA

Autologous CAR-T cells targeting BCMA have induced robust and durable responses in patients with relapsed/refractory multiple myeloma. However, autologous cell therapies face several challenges which will likely limit the number of patients that will have access to these therapies. These limitations include manufacturing failure rates, wait time and supply constraints in addition to other factors such as reimbursement. Allogeneic CAR-T cells can potentially overcome these access challenges, and may have several other advantages over autologous therapies. Allogeneic CAR-T cells are derived from robust healthy donor T cells through a batch manufacturing process, which may result in a highly consistent product with greater potency and enable better safety management. Here we show further development and preclinical data for CTX120, an allogeneic “off the shelf” CAR-T cell targeting BCMA. CTX120 is produced using the CRISPR/Cas9 system to eliminate TCR and MHC class I, coupled with specific insertion of the CAR at the TRAC locus. CTX120 shows consistent and high percent CAR expression from this controlled insertion and exhibits target-specific cytotoxicity and cytokine secretion in response to BCMA positive cell lines. CTX120 CAR-T cells retain their cytotoxic capacity over multiple in vitro re-challenges, demonstrating durable potency and lack of exhaustion. In mouse models of multiple myeloma, CTX120 showed typical CAR-T persistence and eliminated tumors completely, resulting in long-term survival as compared to untreated animals. These data support the ongoing development of CTX120 for treatment of patients with multiple myeloma and further demonstrate the potential for our CRISPR/Cas9 engineered allogeneic CAR-T platform to generate potent CAR-T cells targeting different tumor antigens.

Disclosures: Dar: CRISPR Therapeutics: Employment, Equity Ownership. Henderson: CRISPR Therapeutics: Employment, Equity Ownership. Padalia: CRISPR Therapeutics: Employment, Equity Ownership. Porras: CRISPR Therapeutics: Employment, Equity Ownership. Mu: CRISPR Therapeutics: Employment, Equity Ownership. Kyungah: CRISPR Therapeutics: Employment, Equity Ownership. Police: CRISPR Therapeutics: Employment, Equity Ownership. Kalaitzidis: CRISPR Therapeutics: Employment, Equity Ownership. Terrett: CRISPR Therapeutics: Employment, Equity Ownership. Sagert: CRISPR Therapeutics: Employment, Equity Ownership.

*signifies non-member of ASH